303 related articles for article (PubMed ID: 26259994)
1. Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer.
Yang CF; Gulack BC; Gu L; Speicher PJ; Wang X; Harpole DH; Onaitis MW; D'Amico TA; Berry MF; Hartwig MG
J Thorac Cardiovasc Surg; 2015 Dec; 150(6):1484-92; discussion 1492-3. PubMed ID: 26259994
[TBL] [Abstract][Full Text] [Related]
2. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer.
Shah AA; Berry MF; Tzao C; Gandhi M; Worni M; Pietrobon R; D'Amico TA
Ann Thorac Surg; 2012 Jun; 93(6):1807-12. PubMed ID: 22632486
[TBL] [Abstract][Full Text] [Related]
3. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
[TBL] [Abstract][Full Text] [Related]
4. A Minimally Invasive Approach to Lobectomy After Induction Therapy Does Not Compromise Survival.
Yang CJ; Nwosu A; Mayne NR; Wang YY; Raman V; Meyerhoff RR; D'Amico TA; Berry MF
Ann Thorac Surg; 2020 May; 109(5):1503-1511. PubMed ID: 31733187
[TBL] [Abstract][Full Text] [Related]
5. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemoradiation Shows No Survival Advantage to Chemotherapy Alone in Stage IIIA Patients.
Krantz SB; Mitzman B; Lutfi W; Kuchta K; Wang CH; Howington JA; Kim KW
Ann Thorac Surg; 2018 Apr; 105(4):1008-1016. PubMed ID: 29453000
[TBL] [Abstract][Full Text] [Related]
7. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
[TBL] [Abstract][Full Text] [Related]
8. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.
Yang CF; Adil SM; Anderson KL; Meyerhoff RR; Turley RS; Hartwig MG; Harpole DH; Tong BC; Onaitis MW; D'Amico TA; Berry MF
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1607-13. PubMed ID: 26719403
[TBL] [Abstract][Full Text] [Related]
9. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
10. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer.
Gao SJ; Corso CD; Wang EH; Blasberg JD; Detterbeck FC; Boffa DJ; Decker RH; Kim AW
J Thorac Oncol; 2017 Feb; 12(2):314-322. PubMed ID: 27720827
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the fate of patients who undergo resections of very large, node-negative lung cancers using the National Cancer DataBase.
Liu J; Hancock JG; Moreno AC; Wang Z; Boffa DJ; Detterbeck FC; Kim AW
Eur J Cardiothorac Surg; 2016 Feb; 49(2):596-601. PubMed ID: 25890936
[TBL] [Abstract][Full Text] [Related]
12. Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis.
Chen Y; Peng X; Zhou Y; Xia K; Zhuang W
World J Surg Oncol; 2018 Jan; 16(1):8. PubMed ID: 29338734
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
Kim HK; Cho JH; Choi YS; Zo JI; Shim YM; Park K; Ahn MJ; Ahn YC; Kim K; Kim J
Lung Cancer; 2016 Jun; 96():56-62. PubMed ID: 27133751
[TBL] [Abstract][Full Text] [Related]
15. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis.
Sher DJ; Fidler MJ; Seder CW; Liptay MJ; Koshy M
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):307-16. PubMed ID: 25838187
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
[TBL] [Abstract][Full Text] [Related]
17. Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer.
Cho JH; Kim J; Kim K; Shim YM; Kim HK; Choi YS
World J Surg; 2012 May; 36(5):1199-1205. PubMed ID: 22374538
[TBL] [Abstract][Full Text] [Related]
18. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.
Renaud S; Falcoz PE; Olland A; Reeb J; Santelmo N; Massard G
Interact Cardiovasc Thorac Surg; 2015 Feb; 20(2):222-7. PubMed ID: 25413781
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
Darling GE; Li F; Patsios D; Massey C; Wallis AG; Coate L; Keshavjee S; Pierre A; De Perrot M; Yasufuku K; Cypel M; Waddell T
Eur J Cardiothorac Surg; 2015 Nov; 48(5):684-90; discussion 690. PubMed ID: 25567960
[TBL] [Abstract][Full Text] [Related]
20. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]